Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EVTCY NASDAQ:ICPT NASDAQ:MRTX NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVTCYEvotec$3.05-5.9%$2.86$14.22▼$26.57$1.01B0.982,407 shs98,251 shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ARAREUltragenyx Pharmaceutical$26.120.0%$22.68$18.29▼$42.37$2.57B0.391.75 million shs1.56 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVTCYEvotec0.00%+3.18%+25.58%-8.22%-20.00%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%RAREUltragenyx Pharmaceutical0.00%+5.83%+12.87%+5.79%-21.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVTCYEvotec$3.05-5.9%$2.86$14.22▼$26.57$1.01B0.982,407 shs98,251 shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ARAREUltragenyx Pharmaceutical$26.120.0%$22.68$18.29▼$42.37$2.57B0.391.75 million shs1.56 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVTCYEvotec0.00%+3.18%+25.58%-8.22%-20.00%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%RAREUltragenyx Pharmaceutical0.00%+5.83%+12.87%+5.79%-21.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVTCYEvotec 0.00N/AN/AN/AICPTIntercept Pharmaceuticals 0.00N/AN/AN/AMRTXMirati Therapeutics 0.00N/AN/AN/ARAREUltragenyx Pharmaceutical 2.83Moderate Buy$60.41131.29% UpsideCurrent Analyst Ratings BreakdownLatest ICPT, EVTCY, RARE, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026RAREUltragenyx Pharmaceutical GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.005/6/2026RAREUltragenyx Pharmaceutical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $47.005/6/2026RAREUltragenyx Pharmaceutical WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$27.00 ➝ $26.004/29/2026RAREUltragenyx Pharmaceutical BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $43.004/24/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/16/2026RAREUltragenyx Pharmaceutical Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $67.003/25/2026RAREUltragenyx Pharmaceutical Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/24/2026RAREUltragenyx Pharmaceutical The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $25.003/12/2026RAREUltragenyx Pharmaceutical JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$120.00 ➝ $74.002/18/2026RAREUltragenyx Pharmaceutical Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$128.00 ➝ $79.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVTCYEvotec$572.16M1.76$0.03 per share105.53$2.52 per share1.21ICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39RAREUltragenyx Pharmaceutical$673M3.82N/AN/A($2.40) per share-10.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVTCYEvotec$7.14M$0.417.44N/AN/A20.85%16.02%7.81%N/AICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ARAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-2,272.48%-45.78%N/ALatest ICPT, EVTCY, RARE, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million2/12/2026Q4 2025RAREUltragenyx Pharmaceutical-$1.20-$1.29-$0.09-$1.29$199.60 million$207.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVTCYEvotecN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVTCYEvotec0.532.572.50ICPTIntercept Pharmaceuticals3.124.222.52MRTXMirati TherapeuticsN/A7.547.40RAREUltragenyx PharmaceuticalN/A2.022.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVTCYEvotecN/AICPTIntercept Pharmaceuticals83.81%MRTXMirati TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipEVTCYEvotecN/AICPTIntercept Pharmaceuticals6.20%MRTXMirati Therapeutics3.26%RAREUltragenyx Pharmaceutical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionNo DataMRTXMirati Therapeutics58770.15 million67.86 millionNo DataRAREUltragenyx Pharmaceutical1,37198.49 million93.20 millionOptionableICPT, EVTCY, RARE, and MRTX HeadlinesRecent News About These CompaniesGuggenheim Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00May 8 at 9:32 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Henry Schein (HSIC) and Ultragenyx Pharmaceutical (RARE)May 8 at 9:24 AM | theglobeandmail.comRare disease families find roadmap to drug development at bootcampsMay 7 at 6:30 AM | cnbc.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given New $47.00 Price Target at Wells Fargo & CompanyMay 7 at 4:20 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $26.00 at WedbushMay 7 at 4:20 AM | americanbankingnews.comUltragenyx to Participate at Bank of America’s 2026 Healthcare ConferenceMay 6 at 5:05 PM | markets.businessinsider.comUltragenyx to Participate at Bank of America's 2026 Healthcare ConferenceMay 6 at 4:30 PM | globenewswire.comThere's a New Rare-Earth Stock. Here's What Makes It Stand Out.May 6 at 3:27 PM | barrons.comRARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectMay 6 at 1:01 PM | zacks.comWells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceMay 6 at 10:24 AM | marketbeat.comWedbush Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceMay 6 at 8:49 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RAREMay 6 at 7:59 AM | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Privium Fund Management B.V.May 6 at 6:47 AM | marketbeat.comUltragenyx: Q1 Earnings SnapshotMay 6 at 2:02 AM | khou.comKUltragenyx Pharmaceutical Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPSMay 5, 2026 | marketbeat.comUltragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 5, 2026 | zacks.comUltragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comUltragenyx Reports First Quarter 2026 Financial Results and Corporate UpdateMay 5, 2026 | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 SharesMay 4, 2026 | marketbeat.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $61.18May 4, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026USA Rare Earth's $2.8B Power Play to Secure the Supply ChainBy Jeffrey Neal Johnson | April 23, 20263 Stocks Flashing Rare Buy Signals After the Market's Wildest MonthBy Bridget Bennett | April 21, 2026Investing in Rare Earth Elements: How the REXC ETF Bypasses China’s DominanceBy Jessica Mitacek | April 28, 2026ICPT, EVTCY, RARE, and MRTX Company DescriptionsEvotec OTCMKTS:EVTCY$3.05 -0.19 (-5.86%) As of 05/7/2026Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Intercept Pharmaceuticals NASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Ultragenyx Pharmaceutical NASDAQ:RARE$26.12 -0.01 (-0.04%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$26.84 +0.72 (+2.74%) As of 05/8/2026 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
